Summary
- Profile Type
- Technology offer
- POD Reference
- TOGR20250624006
- Term of Validity
- 24 June 2025 - 24 June 2026
- Company's Country
- Greece
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Greek medtech SME has developed a compact, low-cost, and patented molecular diagnostic platform based on quantitative colorimetric LAMP (qcLAMP), enabling extraction-free testing with PCR-level sensitivity in under 30 minutes. The company is seeking partners for licensing, Original Equipment Manufacturer (OEM) integration, private labeling, and commercial deployment through commercial agreements with technical assistance across healthcare, agrifood, and environmental sectors.
- Full Description
-
The medtech company, located in Greece, is specializing in developing advanced molecular diagnostic solutions. Combining expertise in biomedical engineering, molecular biology, microfluidics, and software integration, the company designs portable, accessible, and high-performance platforms.
Its main innovation, is a patented point-of-care molecular diagnostic system that performs quantitative colorimetric Loop-mediated Isothermal Amplification (qcLAMP) testing. This platform stands out as the first system to combine the low-cost, user-friendly nature of colorimetric diagnostics with real-time, quantitative results, without the need for microfluidics or fluorescent probes. It achieves PCR-level sensitivity while simplifying hardware design, minimizing risk of contamination, and reducing production costs.
The platform is complemented by the company’s proprietary mastermix reagent, designed for extraction-free testing of clinical and non-clinical samples such as saliva, urine, blood, and swabs. It is formulated to resist sample inhibitors and remains stable at ambient temperature, making it highly suitable for field diagnostics and resource-limited environments. The system can deliver results in less than 30 minutes and is capable of testing six samples per run.
The company is seeking partners—such as diagnostic companies, biotech SMEs, agritech or environmental firms, NGOs, or public health authorities—interested in licensing its molecular diagnostic platform or utilizing its OEM services to bring tailored, high-sensitivity testing solutions to market. Ideal collaborators will have established distribution networks and can support product registration and commercialization. The partnership would take the form of a commercial agreement with technical assistance, enabling adaptation of the platform across healthcare, agrifood, environmental, and other sectors. - Advantages and Innovations
- The system combines patented qcLAMP technology with a user-friendly, cost-efficient hardware system to deliver molecular-level sensitivity without the complexity of traditional PCR systems. The device enables sample-to-result testing in under 30 minutes, with a detection limit of just a few copies per reaction. Its production cost is approximately 97% lower than comparable systems, and test kits are projected to cost under ten euros, offering unprecedented affordability. The elimination of microfluidics and use of standard reaction tubes further enhances reliability and operational simplicity. The integrated platform—comprising hardware, software, and reagents—was developed entirely in-house, allowing for rapid customization and deployment. Its extraction-free protocol and compatibility with a broad range of sample types remove the need for expensive equipment or refrigeration, enabling diagnostic applications in remote or underserved regions. The platform empowers healthcare professionals, researchers, and organizations to perform accurate molecular diagnostics with minimal training or infrastructure.
- Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
- IPR notes
- More information upon request.
Partner Sought
- Expected Role of a Partner
-
The company is seeking partners interested in licensing its molecular diagnostic platform and utilizing its OEM services to commercialize tailored solutions across diverse sectors. Ideal partners are those aiming to introduce rapid, affordable, and high-sensitivity molecular testing into new or underserved markets.
More specifically, partners can benefit from device and reagent licensing, OEM production, assay adaptation, regulatory support for Conformité Européenne - In Vitro Diagnostic (CE-IVD) or FDA compliance, and optional technology transfer for local manufacturing. The company is interested in commercial agreements with technical assistance with partners that have established market presence or distribution networks and can drive product registration and commercialization efforts.
The platform, combined with a proprietary LAMP mastermix, enables PCR-level sensitivity without complex processing or cold-chain requirements. It supports testing in decentralized settings using crude samples, making it suitable for applications in healthcare, agrifood, plant diagnostics, environmental safety, and food quality monitoring. Thus, the system is adaptable to a wide range of partners, including diagnostic companies, agritech firms, biotech innovators, NGOs, public health authorities, etc. enabling the development and deployment of customized diagnostic solutions tailored to diverse sector-specific and regional needs. - Type and Size of Partner
- SME 50 - 249
- Big company
- R&D Institution
- SME 11-49
- SME <=10
- University
- Other
- Type of partnership
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06002009 - Molecular design
- 06001005 - Diagnostics, Diagnosis
- 06002007 - In vitro Testing, Trials
- 06002002 - Cellular and Molecular Biology
- Market keywords
- 05001002 - In-vitro diagnostics
- 05004005 - Diagnostic equipment
- 05001005 - Molecular diagnosis
- 04006 - Cellular and Molecular Biology
- 05001001 - Diagnostic services
- Sector Groups Involved
- Health
- Targeted countries
- All countries